How should topical steroids be used in children (including infants under 2 years), regarding appropriate potency, application amount, frequency, duration, and safety precautions?

Topical Steroid Use in Children: Evidence-Based Guidelines

Direct Recommendation

In children with inflammatory skin conditions like atopic dermatitis or psoriasis, use low-to-moderate potency topical corticosteroids (TCS) as first-line therapy, applied once daily for 2-4 weeks initially, with infants and young children requiring the lowest potencies due to increased risk of systemic absorption and hypothalamic-pituitary-adrenal (HPA) axis suppression. 1, 2

---

Potency Selection by Age and Body Site

Infants and Young Children (<2 years)

• Use mild potency TCS exclusively due to higher body surface area-to-volume ratio and increased risk of HPA suppression 1, 2
• Avoid moderate-to-potent preparations in approximately half of infants, as current prescribing patterns show this is a common error 3
• Maximum treatment duration: 2-4 weeks for initial flare control 2

Children (2-12 years)

• Mild-to-moderate potency TCS for trunk and extremities 1, 2
• Low potency only for face, neck, and skin folds to avoid skin atrophy 1, 2
• Moderate potency TCS achieve treatment success (cleared/marked improvement) in 52% versus 34% with mild potency (OR 2.07,95% CI 1.41-3.04) 4
• Potent TCS show even greater efficacy (70% versus 39% success rate, OR 3.71,95% CI 2.04-6.72) but should be reserved for moderate-to-severe disease on non-sensitive areas 4

Adolescents (≥12 years)

• Combination calcipotriol/betamethasone dipropionate can be used once daily for up to 4 weeks (ointment) or 8 weeks (scalp suspension) 1
• Maximum 80 g/week for combination scalp formulation 1

---

Application Frequency and Duration

Frequency

Once daily application is as effective as twice daily for potent TCS (OR 0.97,95% CI 0.68-1.38), making once-daily dosing the preferred regimen to minimize exposure 4

Duration for Active Disease

• Mild-to-moderate potency: up to 12 weeks 5
• High potency: up to 3 weeks maximum 5
• Super-high potency: up to 3 weeks maximum 5
• No specified time limit for low-potency TCS 5

Proactive (Maintenance) Therapy

Weekend (twice-weekly) application of TCS to previously affected areas prevents relapses, reducing flare rate from 58% to 25% (RR 0.43,95% CI 0.32-0.57) in moderate-to-severe atopic dermatitis 4

• Continue for 16-20 weeks after achieving remission 4
• This approach is conditionally recommended for children with moderate-to-very severe AD 2

---

Quantity and Application Method

Fingertip Unit Method

One fingertip unit (FTU) = amount from fingertip to first joint crease, covers approximately 2% body surface area in adults 5

• Adjust proportionally for children's smaller body surface area 5

Typical 6-Month Quantities (90th percentile)

• Infants: <89.5 g total 6
• Children: <135 g total 6
• Adolescents/adults: <304 g total 6

Face-Specific Limits

Maximum 20 g to face over 6 months to minimize telangiectasia risk 6

---

Critical Safety Precautions

High-Risk Areas

• Face, neck, genitals, and skin folds: Use only low-potency TCS due to thinner skin and increased absorption 1, 2, 5
• Antecubital and popliteal fossae: Monitor for steroid-induced atrophy, especially in males 6

Monitoring for Adverse Effects

• Skin atrophy incidence is low (1% across trials) but increases with higher potency: 16 cases with very potent, 6 with potent, 2 with moderate, 2 with mild 4
• HPA suppression risk: Highest in infants, with high/ultra-high potency TCS, large surface area application, and occlusion 1, 5
• One study reported transient mild HPA suppression in 1/31 adolescents using combination betamethasone/calcipotriol, which resolved 4 weeks after discontinuation 1

Avoiding Rebound Flares

Do not abruptly discontinue high-potency TCS; transition to lower potency or alternative treatment to prevent rebound 1

---

Steroid-Sparing Strategies

Rotational Therapy

Consider rotating between TCS, topical calcineurin inhibitors (tacrolimus 0.1% for face/genitals), vitamin D analogues, emollients, and tar-based therapies to reduce steroid overreliance 1

Adjunctive Treatments

• Regular emollients have short- and long-term steroid-sparing effects 2
• Wet-wrap therapy with TCS: Effective for moderate-to-very severe AD, use for 3-7 days (maximum 14 days in severe cases) 2

When to Escalate Beyond Topicals

If children require >1-2 drops/day prednisolone acetate 1% equivalent for ≥3 months despite topical therapy, consider adding systemic therapy (biologics, JAK inhibitors, or cyclosporine for refractory cases) 7, 2

---

Special Populations

Infants <2 Years with Persistent Disease

Most topical steroids are not FDA-approved or studied in this age group 8

• Off-label use may be necessary when hydration and emollients fail 8
• Use lowest effective potency with close monitoring 8, 2

Pregnancy and Lactation

TCS can work safely and effectively in pregnant or lactating patients 5

---

Common Prescribing Errors to Avoid

1. Prescribing moderate-to-potent preparations in infants (occurs in ~50% of cases) 3
2. Omitting frequency of dosing (21.6% of prescriptions) and duration (43.6%) 3
3. Using controversial vehicle dilution techniques (base cream dilution prescribed in 11-32% of cases) 3
4. Co-prescribing multiple corticosteroid preparations simultaneously 3
5. Applying high-potency TCS to face/folds without time limits 1, 2

---

Key Takeaway Algorithm

1. Select potency: Mild for infants; mild-moderate for children's trunk/extremities; low only for face/folds at any age
2. Apply once daily (not twice) for active disease
3. Limit duration: 2-4 weeks for initial control (up to 12 weeks for mild-moderate potency)
4. Transition to weekend (proactive) therapy for maintenance in moderate-severe cases
5. Monitor for atrophy and HPA suppression, especially in infants and with potent preparations
6. Rotate with steroid-sparing agents to minimize long-term exposure